AGN:NYE-Allergan plc (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 193.02

Change

0.00 (0.00)%

Market Cap

USD 63.66B

Volume

0.01B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Allergan plc (AGN) Stock Analysis:
Based on the Allergan plc stock forecasts from 0 analysts, the average analyst target price for Allergan plc is not available over the next 12 months. Allergan plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allergan plc is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Allergan plc’s stock price was USD 193.02. Allergan plc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Allergan plc
No recent average analyst rating found for Allergan plc

About

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and Inter ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-18 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

-3.32 (-1.86%)

USD470.55B 24.10 16.37
PFE Pfizer Inc

-0.94 (-1.83%)

USD288.06B 13.32 8.74
LLY Eli Lilly and Company

-6.21 (-2.06%)

USD286.38B 44.80 33.44
ABBV AbbVie Inc

-2.35 (-1.52%)

USD273.51B 22.20 13.62
MRK Merck & Co. Inc

-0.90 (-0.97%)

USD235.18B 16.65 12.55
NVS Novartis AG

-0.24 (-0.27%)

USD194.29B 8.18 6.24
BMY Bristol-Myers Squibb Company

-1.20 (-1.53%)

USD163.98B 27.28 10.03
GSK GlaxoSmithKline plc

-1.08 (-2.42%)

USD112.79B 18.02 13.54

ETFs Containing AGN

Symbol Name Weight Mer Price(Change) Market Cap
PBI Pitney Bowes Inc 0.00 % 0.00 %

-0.23 (-4.72%)

USD0.84B
ISPA:F iShares (DE) I - iShares .. 0.00 % 0.46 %

+0.12 (+0.39%)

USD1.97B
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.65 %

+0.40 (+0.15%)

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -11.92% N/A N/A N/A N/A
Dividend Return 3.98% N/A N/A N/A N/A
Total Return -7.94% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.79% N/A N/A N/A N/A
Dividend Return 1.13% N/A N/A N/A N/A
Total Return 2.92% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.29% N/A N/A N/A N/A
Risk Adjusted Return 15.99% N/A N/A N/A N/A
Market Capitalization 63.66B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.00 N/A N/A N/A N/A
Price/Book Ratio 1.10 N/A N/A N/A N/A
Price / Cash Flow Ratio 8.79 N/A N/A N/A N/A
EV/EBITDA 28.44 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -4.15% N/A N/A N/A N/A
Return on Invested Capital -0.19% N/A N/A N/A N/A
Return on Assets 0.74% N/A N/A N/A N/A
Debt to Equity Ratio 31.14% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 1.53% N/A N/A N/A N/A
Short Ratio 3.22 N/A N/A N/A N/A
Short Percent 4.56% N/A N/A N/A N/A
Beta 1.20 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike